A Multicenter, Uncontrolled, Open-label Trial to Investigate the Long-term Tolerability, Safety, and Efficacy of Brexpiprazole Once-weekly (QW) Formulation Administered Once Weekly for 52 Weeks in Patients With Schizophrenia

NCT05326347 Phase 3 ACTIVE_NOT_RECRUITING

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

Details

Lead sponsor	Otsuka Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	190
Start date	2022-05-31
Completion	2025-09

Conditions

• Schizophrenia

Interventions

• OPC-34712FUM/ Brexpiprazole fumarate

Primary outcomes

• The frequency of Adverse Events — From baseline to week 52

Countries

Japan